Ventas, Inc. (VTR) Q3 2024 Earnings Call Transcript
VTR's Q3 results reflect a year-over-year rise in revenues. The total property same-store NOI improves on strong performance across the business segments.
Although the revenue and EPS for Ventas (VTR) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Ventas (VTR) came out with quarterly funds from operations (FFO) of $0.80 per share, in line with the Zacks Consensus Estimate. This compares to FFO of $0.75 per share a year ago.
Healthcare REIT Ventas slightly raised the lower end of its annual funds from operations (FFO) forecast on Wednesday, expecting continued strong performance from its assisted living and senior housing properties.
Get a deeper insight into the potential performance of Ventas (VTR) for the quarter ended September 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
VTR's Q3 earnings are likely to have benefited from favorable SHOP operating trends, healthy demand for life-science real estate assets and accretive investments.
I've been holding on to this dividend-paying REIT, but there is a better option out there if you have new money to put to work.
VTR is poised to gain from a favorable demand in senior housing, backed by an expected rise in senior citizens' population.
To improve patient care facilities, VTR announces reaching an agreement with Kindred and ScionHealth regarding 23 long-term acute care hospitals.
Rising healthcare spending and aging population aid Ventas' senior housing operating portfolio. However, tenant concentration and high interest rates are risks.
Ventas is a healthcare REIT focused on Senior Housing, Outpatient Medical & Research, and Net Lease properties, primarily in the United States. The REIT has outperformed the Vanguard Real Estate Index Fund ETF in 2024 with a 22% total return. While Q2 2024 results were excellent and the company increased its guidance, I think the normalized FFO multiple and market-implied cap rate are quite elevated.